dc.contributorPizarro, J.G., Centros de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona 08028, Spain; Folch, J., Facultat de Medicina i Ciències de la Salut, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Universitat Rovira i Virgili, C/St. Llorenç 21, Reus (Tarragona), 43201, Spain; Junyent, F., Centros de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona 08028, Spain, Facultat de Medicina i Ciències de la Salut, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Universitat Rovira i Virgili, C/St. Llorenç 21, Reus (Tarragona), 43201, Spain; Verdaguer, E., Departament de Biologia Cellular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain; Auladell, C., Departament de Biologia Cellular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain; Beas-Zarate, C., Departamento de Biología Celular y Molecular, CUCBA, Instituto Mexicano Del Seguro Social (IMSS), Sierra Mojada 800, Col. Independencia, Guadalajara, Jalisco 44340, Mexico; Pallàs, M., Centros de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona 08028, Spain; Camins, A., Centros de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona 08028, Spain
dc.contributorBeas-Zárate, Carlos., Universidad de Guadalajara. Centro Universitario de Ciencias Biológicas y Agropecuarias
dc.creatorPizarro, J.G.
dc.creatorFolch, J.
dc.creatorJunyent, F.
dc.creatorVerdaguer, E.
dc.creatorAuladell, C.
dc.creatorBeas-Zárate, Carlos
dc.creatorPallas, M.
dc.creatorCamins, A.
dc.date.accessioned2015-11-18T23:43:46Z
dc.date.accessioned2023-07-04T02:30:25Z
dc.date.available2015-11-18T23:43:46Z
dc.date.available2023-07-04T02:30:25Z
dc.date.created2015-11-18T23:43:46Z
dc.date.issued2011
dc.identifierhttp://hdl.handle.net/20.500.12104/63322
dc.identifier10.1007/s10495-011-0583-3
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-79955844072&partnerID=40&md5=2328398039c118dcc950b839124f3a25
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/7261925
dc.description.abstractIn the present study dopaminergic neuroblastoma B65 cells were exposed to Camptothecin (CPT) (0.5-10 μM), either alone or in the presence of roscovitine (ROSC). The results show that CPT induces apoptosis through the activation of ataxia telangiectasia mutated (ATM)-induced cell-cycle alteration in neuroblastoma B65 cells. The apoptotic process is mediated through the activation of cystein proteases, namely calpain/caspases. However, whereas a pan-caspase inhibitor, zVADfmk, inhibited CPT-mediated apoptosis, a calpain inhibitor, calpeptin, did not prevent cell death. Interestingly, CPT also induces CDK5 activation and ROSC (25 μM) blocked CDK5, ATM activation and apoptosis (as measured by caspase-3 activation). By contrast, selective inhibition of ATM, by KU55933, and non-selective inhibition, by caffeine, did not prevent CPT-mediated apoptosis. Thus, we conclude that CDK5 is activated in response to DNA damage and that CDK5 inhibition prevents ATM and p53ser15 activation. However, pharmacological inhibition of ATM using KU55933 and caffeine suggests that ATM inhibition by ROSC is not the only mechanism that might explain the anti-apoptotic effects of this drug in this apoptosis model. Our findings have a potential clinical implication, suggesting that combinatory drugs in the treatment of cancer activation should be administered with caution. © 2011 Springer Science+Business Media, LLC.
dc.relationApoptosis
dc.relation16
dc.relation5
dc.relation536
dc.relation550
dc.relationScopus
dc.relationWOS
dc.titleAntiapoptotic effects of roscovitine on camptothecin-induced DNA damage in neuroblastoma cells
dc.typeArticle


Este ítem pertenece a la siguiente institución